Researchers develop gene therapy to reverse pulmonary arterial hypertension

June 03, 2005

A University of Alberta research team has discovered important new information they hope will lead to more effective treatments for pulmonary arterial hypertension (PAH)-a deadly form of high blood pressure in the pulmonary arteries caused by uncontrolled cell growth. Therapies are currently limited for a disease that can lead to heart failure and death within a few years.

The researchers have shown that Survivin, a protein almost exclusively expressed in cancer, is also heavily expressed in both human and animal lung arteries with PAH. Survivin is an inhibitor of apoptosis-or programmed cell death-which promotes cancer by suppressing the body's ability to limit excessive cell growth.

Armed with this new information and using animal models, the researchers developed a nebulized and inhaled gene therapy to deliver an inactive Survivin-mutant via a virus-known in science as a "dominant negative construct"-effectively inhibiting endogenous Survivin. The therapy reversed PAH in rats and improved their heart function and their survival, thus holding out some promising avenues of treatment for human PAH. The team members believe that as in cancer, Survivin drives excessive cell growth in the PAH lung blood vessels.

"The most intriguing aspect," explains principal researcher Evangelos Michelakis, "is we've shown for the first time that this cancer protein is also expressed within the blood vessels of the lung in patients suffering with PAH, but not in normal human blood vessels, making survivin a very attractive target for selective intervention.

"This makes the proliferation of lung blood vessels in this disease a 'form of cancer' or a form of neoplasia to be more precise, first proposed by Drs. Voelkel and Tuder from the University of Colorado. We've demonstrated for the first time that, like cancer, apoptosis is suppressed in the lung blood vessel wall in this disease."

"Our biggest challenge in treating PAH is the fact we don't know what makes the cells in the lung blood vessel wall grow excessively," says the University of Alberta cardiology professor and Canada Research Chair holder. "And therapies also have to target the lung blood vessels and spare the normal cells in the rest of the body."

The paper is entitled Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. It's published in the June issue of The Journal of Clinical Investigation. In an accompanying editorial entitled Lessons learned from cancer may help in the treatment of pulmonary hypertension, written by French researcher Serge Adnot, the journal stated: "These findings raise important issues regarding the role of survivin in the pathogenesis of PAH, its value as a prognostic indicator, and its use as a target for new therapeutic strategies.\\\\\\\

University of Alberta

---

---

	Pulmonary Arterial Hypertension (The Facts) by Clive Handler (Author), Gerry Coghlan (Author) Pulmonary arterial hypertension (PAH) is a high blood pressure in the arteries that supply the lungs with blood. Patients with mild PAH, particularly young patients, may feel quite well and get breathless or tired only with vigorous exertion. Those with severe PAH may get breathless on minimal exertion and feel tired, exhausted and experience chest pain, forceful heart beats, dizzy turns, loss of appetite, and have swelling of the legs due to fluid retention. This book will help patients and their families understand what PAH is, and advise them on how to cope with their illness. In the UK patients with PAH are referred to one of the eight National Pulmonary Hypertension centres staffed by a team of specialist doctors, nurses, pharmacists, and other staff who are experienced and...
	Pulmonary Arterial Hypertension: Diagnosis and Evidence - Based Treatment by Robyn Barst (Author) First book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patientsFrom the PAH Association, the leading experts in fieldIncorporates the latest AACP management guidelinesIncludes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical TreatmentAimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH
	A Clinician's Guide to Pulmonary Arterial Hypertension by Simon Stewart (Author) A Clinician's Guide to Pulmonary Arterial Hypertension, Second Edition enhances the overall 'PAH awareness' of the wider clinical community, and outlines the need for screening, effective diagnosis and beneficial treatment. Topics include:
	Pulmonary Arterial Hypertension and Interstitial Lung Diseases: A Clinical Guide by Robert P. Baughman (Editor), Roberto G. Carbone (Editor), Giovanni Bottino (Editor) Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 150 disorders characterized by scarring or fibrosis of the lungs. In Pulmonary Arterial Hypertension and Interstitial Lung Disease: A Clinical Guide, renowned experts provide a state-of-the-art overview of the problems seen by physicians in the clinical management of ILDs. Divided into two sections, the first part provides and update on general issues and introduces both interstitial lung disease and associated pulmonary hypertension. A detailed analysis of the pathology of the various interstitial lung diseases is also provided. The second part addresses specific categories of disease. Bronchiolitis, hypersensitivity pneumonitis, and other conditions are covered, and the use of inspiratory and...
	Pulmonary Arterial Hypertension, An Issue of Clinics in Chest Medicine, 1e (The Clinics: Surgery) by H. Palevsky (Author) The issue provides a valuable, updated resource on PAH, including topics such as epidemiology; assessing response to therapy; pathology; genetics and mediators; diagnosis; standard therapies; endothelin receptor antagonists prostanoids, and nitric oxide pathway in the treatment of PAH; combination therapy and new types of agents; surgical therapies; porto-pulmonary hypertension; and pulmonary hypertension associated with respiratory diseases, left heart disease, congenital heart disease, and thromboembolic disease. This issue provides a definitive handbook on the most important topics in PAH.
	Pulmonary Arterial Hypertension: Pocketbook by Stewart Simon (Author) This pocketbook is a concise summary of latest evidence-based information on the diagnosis, assessment and treatment of pulmonary arterial hypertension. Dr Simon Stewart is one of the world's leading nursing experts on cardiac disease, especially heart failure. Highly illustrated, clearly and succinctly written, the book provides an introduction to pulmonary arterial hypertension. It contains clear guidelines for the effective treatment of pulmonary arterial hypertension and emphasizes the need for screening of high-risk patients and outlines the range and effectiveness of treatment options once PAH has been diagnosed.
	Pulmonary Hypertension (Contemporary Cardiology) by Nicholas S. Hill (Author), Harrison W. Farber (Author) This timely volume addresses the areas of pathophysiology and therapy of pulmonary hypertension, which have seen exciting developments over the past decade. The discoveries of endothelin overexpression as well as prostacyclin and nitric oxide deficiency in association with pulmonary hypertension have led to important therapeutic insights. The new therapies have led to significant improvements in patient function, quality of life and survival. In this book, expert authors describe these new therapies. It will be of interest not only to cardiologists, pulmonary specialists and rheumatologists, but also many nurses and pharmacotherapists.
	Adult Congenital Heart Disease and Pulmonary Arterial Hypertension: The Texas Adult Congenital Heart Program Experience (DOI: 10.3810/pgm.2011.11.2493) (Postgraduate Medicine) by JTE Multimedia Congenital heart disease (CHD) is a common structural defect of the heart or major blood vessels. Patients with adult congenital heart disease (ACHD) have medical needs that are distinct from those of pediatric patients with CHD, and the transition into adult health care is important for management of the patient with ACHD. A large proportion of patients with CHD develop diseases and complications associated with the long-term stress of intracardiac shunts. Pulmonary arterial hypertension (PAH) is a significant complication of some CHD lesions. The treatment of these patients remains challenging due to their combined heart and lung disease, and multidisciplinary care is ofen necessitated for a variety of secondary conditions. A number of treatment options are available for the management...
	Screening systemic sclerosis patients allows earlier PAH diagnosis, treatment.(Cardiovascular Medicine)(Pulmonary arterial hypertension): An article from: Internal Medicine News by Mitchel L. Zoler (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on December 1, 2004. The length of the article is 633 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Screening systemic sclerosis patients allows earlier PAH diagnosis, treatment.(Cardiovascular Medicine)(Pulmonary arterial hypertension) Author: Mitchel L. Zoler Publication: Internal Medicine News (Magazine/Journal) Date: December 1, 2004 Publisher: International Medical News Group Volume: 37 Issue: 23 Page: 45(1) Distributed by Thomson...
	Big change in pulmonary arterial hypertension Tx. (New Agents Approach Market).: An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on April 1, 2002. The length of the article is 580 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Big change in pulmonary arterial hypertension Tx. (New Agents Approach Market). Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: April 1, 2002 Publisher: International Medical News Group Volume: 32 Issue: 7 Page: 35(1) Article Type: Product/Service Evaluation Distributed by Thomson...